Front Page Demo Slide


LATEST NEWS:   Novartis psoriasis drug maintains efficacy after four years: study - ZURICH (Reuters) - Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.
LATEST NEWS:   FDA warns against use of homeopathic teething products - (Reuters) - The U.S. Food and Drug Administration warned against the use of homeopathic teething tablets and gels on Friday, citing potential risks to infants and children and prompting CVS Health Corp Inc to withdraw the products.
LATEST NEWS:   Depomed wins Nucynta patent dispute; may spur sale talks - (Reuters) - A court ruled in Depomed Inc's favor in a patent dispute over its opioid drug, Nucynta, a decision that could help pave the way for the drug maker to explore a sale.
LATEST NEWS:   Breast cancer treatments vary widely in cost and complications - (Reuters Health) - Women with early-stage breast cancer may have fewer treatment complications and lower costs when they don’t get a mastectomy followed by reconstructive surgery, a U.S. study suggests.
LATEST NEWS:   Doctors don't communicate well about terminally ill patients - (Reuters Health) - Cancer specialists and primary care physicians are not communicating very well about the end-of-life concerns of the patients they share - and according to one new study, they often rely on those patients to convey information back and forth.
LATEST NEWS:   Misperception about skin cancer prominent among minority groups - (Reuters Health) - Uninsured, immigrant and minority communities in the United States may not be as aware of skin cancer as they should be, a recent study suggests.
LATEST NEWS:   Labels don't always guarantee foods are free of gluten - (Reuters Health) - Some foods that don’t appear to contain wheat or gluten based on package labeling may still have trace amounts of these ingredients, a company-funded study suggests.
LATEST NEWS:   Regeneron's Eylea combination therapy fails mid-stage study - (Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
LATEST NEWS:   Thailand confirms first Zika-linked microcephaly in Southeast Asia - BANGKOK (Reuters) - Thailand reported on Friday the first confirmed cases in Southeast Asia of microcephaly linked to mosquito-borne Zika, as the World Health Organization urged action against the virus across the region.